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small-cell lung canceains the standard of care for functionally operable early-stage non-
r (NSCLC) and resectable stage IIIA disease. The role of invasive stag-ing and restaging techniques is currently being debated, but they provide the largest biopsy
samples which allow for precise mediastinal staging. Different types of operative proce-
dures are currently available to the thoracic surgeon, and some of these interventions
can be performed by video-assisted thoracic surgery (VATS) with the same oncological
results as those by open thoracotomy. The principal aim of surgical treatment for NSCLC
is to obtain a complete resection which has been precisely defined by a working group of
the International Association for the Study of Lung Cancer (IASLC). Intraoperative staging
of lung cancer is of utmost importance to decide on the extent of resection according to
the intraoperative tumour (T) and nodal (N) status. Systematic nodal dissection is generally
advocated to evaluate the hilar and mediastinal lymph nodes which are subdivided into
seven zones according to the most recent 7th tumour-node-metastasis (TNM) classifica-
tion. Lymph-node involvement not only determines prognosis but also the administration
of adjuvant therapy.
In 2011, a new multidisciplinary adenocarcinoma classification was published introducing
the concepts of adenocarcinoma in situ and minimally invasive adenocarcinoma. This
classification has profound surgical implications. The role of limited or sublobar resection,
comprising anatomical segmentectomy and wide wedge resection, is reconsidered for
early-stage lesions which are more frequently encountered with the recently introduced
large screening programmes. Numerous retrospective non-randomised studies suggest
that sublobar resection may be an acceptable surgical treatment for early lung cancers, also
when performed by VATS.
More tailored, personalised therapy has recently been introduced. Quality-of-life parame-
ters and surgical quality indicators become increasingly important to determine the
short-term and long-term impact of a surgical procedure. International databases currently
collect extensive surgical data, allowing more precise calculation of mortality and morbid-
ity according to predefined risk factors. Centralisation of care has been shown to improve
results. Evidence-based guidelines should be further developed to provide optimal staging
and therapeutic algorithms.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
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Thoracic surgery remains a major diagnostic and therapeutic
modality for patients with non-small-cell lung cancer
(NSCLC). However, many controversial issues remain regard-
ing its precise role and application. Invasive staging and
restaging procedures are applied more selectively with the
introduction of endosonographic techniques. When discuss-
ing the different types of operative procedures that are avail-
able to the thoracic surgeon, a distinction has to be made
between early-stage disease (stages IA/B and IIA/B), locore-
gionally advanced disease (stages IIIA/B), and metastatic dis-
ease (stage IV). Indications for surgical treatment of NSCLC
are tailored according to the most recent 7th tumour-node-
metastasis (TNM) classification, taking into account that sur-
gery for locoregionally advanced disease remains a highly
controversial topic. Intraoperative staging of lung cancer is
extremely important to determine the extent of resection
according to the intraoperative tumour (T) and nodal (N) sta-
tus. Systematic nodal dissection is generally advocated to
determine the precise nodal involvement. In 2011, a new ade-
nocarcinoma classification was published with adenocarci-
noma in situ and minimally invasive adenocarcinoma as
new categories. The surgical implications of this relate mainly
to the role of limited, sublobar resection. Especially when part
of a combined modality regimen, surgical resection has a pro-
found influence on quality of life. Prospective data on short-
and long-term effects have recently become available, allow-
ing better counselling of our patients.
In this review invasive mediastinal staging and restaging
are discussed, as well as indications for surgical resection,
intraoperative staging, the new adenocarcinoma classifica-
tion and its surgical implications, quality of life after lung
resection, and finally surgical quality indicators, including
the relationship between volume and outcome.Table 1 – Invasive mediastinal staging and restaging
techniques.
Cervival mediastinoscopy
Repeat mediastinoscopy, remediastinoscopy
Anterior mediastinoscopy (mediastinotomy)
Extended mediastinoscopy (combination cervical + anterior)
Scalene lymph-node biopsy
Video-assisted mediastinal lymphadenectomy (VAMLA)
Transcervical extended mediastinal lymphadenectomy
(TEMLA)
Video-assisted thoracic surgery (VATS), thoracoscopy2. Invasive mediastinal staging and restaging
of lung cancer
2.1. Importance of lymph-node staging
In the absence of distant metastases, the prognosis of a pa-
tient with lung cancer largely depends on locoregional
lymph-node involvement. Pathological staging remains the
gold standard in quantifying the extent of locoregional and
mediastinal lymph-node involvement. Patients with ipsilat-
eral hilar or intrapulmonary lymph-node metastases (N1) are
not precluded from surgery as complete resection provides a
good long-term outcome when combined with adjuvant che-
motherapy. Patients with ipsilateral mediastinal lymph-node
metastases (N2) are currently treatedwith combinedmodality
therapy, mostly chemoradiation. Only patients with limited
N2 disease, in whom down-staging is obtained after induction
therapy, may be considered for surgical resection. Patients
with contralateral mediastinal or supraclavicular lymph-node
involvement (N3) are currently considered unsuitable candi-
dates for surgery due to poor long-term prognosis with mul-
timodality therapy, including surgery.Currently available invasive staging techniques are sum-
marised in Table 1. Due to refinements in non-invasive and
minimally invasive, endosonographic staging techniques,
the role of surgical invasive staging and restaging has been
redefined.
2.2. Invasive mediastinal staging
Mediastinoscopywas introduced by Carlens in 1959 as ameth-
od for inspection and tissue biopsy in the superior mediasti-
num; it still holds true today [1]. With the routine use of
mediastinoscopy, the rate of exploratory thoracotomies could
be drastically reduced. Mediastinoscopy is associatedwith low
morbidity (2%) and lowmortality (0.08%) but remains an inva-
sive procedure requiring general anaesthesia [2].With the sub-
sequent advent of new imaging techniques – initially
computed tomography (CT), later on positron emission
tomography (PET) and integrated PET–CT followed by themin-
imally invasive endosonographic techniques, endoscopic
ultrasound (EUS) and endobronchial ultrasound (EBUS) – the
precise role ofmediastinoscopy is amatter of constant debate.
The different staging techniques that belong to the surgi-
cal armamentarium are listed in Table 1. Comparison of
mediastinal lymph-node stations that can be reached by
endosonography and invasive surgical staging is given in Ta-
ble 2. Mediastinoscopy provides a thorough exploration of the
superior mediastinum, allowing not only large biopsy sam-
ples of the different nodal stations in the superior mediasti-
num, but also evaluation of possible mediastinal extension
of a primary lung cancer. In this way, sufficient tissue be-
comes available for detailed molecular analysis.
Anterior mediastinoscopy, which is called anterior medi-
astinotomy when a rib cartilage has to be removed, provides
access to the anterior mediastinum and lymph-node stations
5 and 6 on the left side. Some centres have experience with
extended mediastinoscopy which is a combination of cervical
and anterior mediastinoscopy by the same cervical incision
[3]. Also evaluation of the supraclavicular lymph-node station
1 is possible by the latter incision. In many centres anterior
mediastinoscopy is now replaced by thoracoscopy or video-
assisted thoracic surgery (VATS), allowing a complete explora-
tion of the ipsilateral pleural cavity.
The reported positive predictive value (PPV) and negative
predictive value (NPV) of mediastinoscopy for staging of
NSCLC are 100% and 96%, respectively [4]. When an extensive
lymph-node dissection is performed by video-assisted medi-
Table 2 – Mediastinal staging.
LN EBUS EUS Cervical
mediastinoscopy
VAMLA
TEMLA
VATS
L R
1 + + + + – –
2R + – + + – +
2L + + + + – –
4R + – + + – +
4L + + + + – –
5 – – – + + –
6 – – – + + –
7 + + + + + +
8 – + – + + +
9 – + – – + +
EBUS, endobronchial ultrasound; EUS, oesophageal ultrasound; LN,
lymph-node station, L, left; R, right; TEMLA, transcervical extended
mediastinal lymphadenectomy; VAMLA, video-assisted mediasti-
nal lymphadenectomy; VATS, video-assisted thoracic surgery.
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mediastinal lymphadenectomy (TEMLA) procedures, the rate
of false negatives becomes extremely low [5–7].
Combination of EBUS and EUS – so-called ‘medical medi-
astinoscopy’ – provides access to a larger number of lymph-
node stations than classical cervical mediastinoscopy. Both
EBUS and EUS can be performed under local anaesthesia,
which is a major advantage. Rapid on-site examination
(ROSE) by the pathologist definitely increases accuracy. When
a positive result is obtained, surgical invasive staging is
avoided. For this reason EBUS and EUS are currently the pre-
ferred examinations after non-invasive tests, and in experi-
enced hands a high accuracy is reported.
In the randomised Assessment of Surgical Staging versus
Endosonographic Ultrasound in Lung Cancer: a Randomized
Clinical Trial (ASTER) study, 241 patients with resectable, sus-
pected or proven NSCLC, in whom mediastinal staging was
indicated on the basis of CT or PET findings, were enrolled
into a randomised controlled multicentre study comparing
different strategies for mediastinal lymph-node staging [8].
Nodal metastases were found in 35% by surgical staging
alone, 46% by endosonography (EBUS and EUS) and 50% by
endosonography followed by surgical staging. NPVs were 86,
85 (P = 0.47) and 93% (P = 0.18), respectively [8].
In a prospective study of 153 patients, Yasufuku and col-
leagues chose EBUS as the initial investigation for mediastinal
lymph-node staging followed by mediastinoscopy [9]. If both
were negative, a thoracotomy was performed. Prevalence of
N2/N3 disease was 35%. EBUS had an NPVof 91% and medias-
tinoscopy of 90%, so the conclusion of this study was that
EBUS may replace mediastinoscopy. In a recent retrospective
study from the same centre, the sensitivities and NPVs of
EBUS in evaluating clinical N0 or N1 disease were 76% and
96%, respectively [9]. The role of endobronchial ultrasound-
guided transbronchial needle aspiration for differentiating
stage I from stage II lung cancer: poster presentation at the
49th Annual Meeting of the Society of Thoracic Surgeons,
Los Angeles, California, January 26–30, 2013). However, it
should be mentioned that this group comprises thoracic sur-
geons having a large experience with endosonographic andinvasive staging techniques. Can these results from a high-
volume dedicated centre be duplicated in everyday practice?
Cerfolio published a retrospective review of 234 patients
with NSCLC who were staged by EBUS or EUS for suspected
N2 disease on CT or PET–CT [10]. Mediastinoscopy was per-
formed when EBUS/EUS were negative. NPVs for detecting
N2 disease by EBUS, EUS and mediastinoscopy were 79%,
80% and 93%, respectively. EBUS was found to be falsely neg-
ative in 28%, and EUS in 22% of the cases. In a retrospective
study from a single institution by Defranchi, 494 patients, sus-
pected of lung cancer, underwent EBUS [11]. A negative result
was followed by mediastinoscopy. Of the patients with suspi-
cious mediastinal lymph nodes, 28% still had N2 disease con-
firmed by mediastinoscopy despite a negative EBUS. In this
way, negative EBUS/EUS results should still be confirmed by
mediastinoscopy.
The current indications for surgical mediastinal staging
are a matter of judgment and precise knowledge of the vari-
ous staging modalities and their results. None of the available
techniques can be expected to provide perfect results. The
main question becomes what false-negative rate one is will-
ing to accept. In patients with suspected mediastinal
lymph-node involvement by non-invasive techniques, evalu-
ation by EBUS/EUS followed by mediastinoscopy in cases
where no positive lymph nodes are found by endosonograph-
ic techniques has produced excellent results, with a reported
increase in sensitivity for detection of mediastinal nodal dis-
ease of up to 93% [8]. In concordance with the European Soci-
ety of Thoracic Surgeons (ESTS) guidelines, positive CT, PETor
PET–CT findings should be cytologically or pathologically con-
firmed [12]. EBUS and EUS are complementary to surgical
invasive staging techniques with a high specificity but low
NPV. Therefore, an invasive surgical technique is still indi-
cated if EBUS/EUS yield a negative result. Fig. 1 provides a flow
chart of mediastinal staging of NSCLC that is currently used
at the Antwerp University Hospital in Belgium.
2.3. Invasive mediastinal restaging
Most patients with pathologically proven N2 disease detected
during preoperativework-up will be treated by induction ther-
apy. Themediastinum can be principally restaged by the same
techniques as applied in primary staging. At the present time,
CT, PETand PET–CTare not accurate enough to make final fur-
ther therapeutic decisions after induction therapy. The accu-
racy of CT in restaging after induction therapy is only 58%
[13]. PET scanning is more accurate than CT for mediastinal
restaging, with a reported PPV to detect persisting nodal dis-
ease of 73% [14]. In detecting residual N2 disease, however,
PPVwas less than20%.Theuse of PET–CT fusion images signif-
icantly increases the accuracy throughbetter localisationof fo-
cal isotope uptake in mediastinal nodes [15]. However, 20%
false-negative and 25% false-positive rates have been reported
[16]. In caseswhere there is a suspicion of residualmediastinal
disease, invasive biopsies are still required.
Endosonographic techniques are also used for restaging.
However, their false-negative rates remain high, ranging be-
tween 20% and 30% [17,18]. Therefore, negative findings
should still be confirmed by surgical restaging.
Fig. 1 – Flow chart for mediastinal staging of non-small-cell lung cancer (NSCLC) in the Antwerp University Hospital. ES,
endosonographic technique (endobronchial or endoscopic ultrasound); MS, mediastinoscopy; MMT, multimodality
treatment; PET–CT, integrated positron emission tomography and computed tomography.
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induction therapy are summarised in Table 3 [15,19–24].
Remediastinoscopy offers the advantage of providing patho-
logical evidence of response after induction therapy. In this
way, it remains a valuable tool to select patients for surgical
resection [25]. Survival clearly depends on the findings of
remediastinoscopy, patients with a positive repeat mediasti-
noscopy having a poor prognosis compared to those with a
negative remediastinoscopy [21]. In a combined series of 104
patients, nodal status was the only significant factor related
to survival in multivariate analysis [22].
An alternative approach consists of the use of minimally
invasive, endosonographic procedures to obtain an initial
proof of mediastinal nodal involvement. Mediastinoscopy is
subsequently performed after induction therapy to evaluate
response [26]. In this way, a technically more difficult remedi-
astinoscopy can be avoided.
Only one study has reported the results of VATS for restag-
ing after induction therapy [27]. In this Cancer and Leukemia
Group B (CALGB) 39803 trial a negative result of VATS was de-
fined as negative lymph-node biopsies from at least three
lymph-node stations, whereas a positive result consisted of
a pathological proof of persisting N2 disease in the mediasti-
num or the demonstration of pleural carcinomatosis. Sensi-
tivity, specificity and NPV of VATS for restaging were 67%,
100% and 73%, respectively.Table 3 – Results of remediastinoscopy after induction therapy.
Author, year Ref. n IT Morbidity
Pitz, 2002 19 15 CT 0
Stamatis, 2005 20 165 CT–RT 2.5
De Waele, 2006 21 32 CT (n = 26) CT–RT (n = 6) 3.1
De Leyn, 2006 15 30 CT 0
De Waele, 2008a 22 104 CT (n = 79) CT–RT (n = 25) 3.9
Marra, 2008b 23 104 CT–RT 1.9
Call S, 2011c 24 84 CT (n = 49) CT–RT (n = 35) 4.0
Ref., reference; n, number of patients; IT, induction therapy; CT, chemoth
a Combined, updated series.
b Subset of patients of Stamatis, 2005 [20].
c Results of restaging after induction therapy.In the restaging guidelines published by the ESTS an inva-
sive technique providing cytological or histological informa-
tion is also recommended [12]. Endoscopic or surgical
invasive procedures may be utilised, the precise choice
depending on the availability of the technique and expertise
of the centre [12]. This policy was confirmed in a recent sys-
tematic review on restaging after induction therapy for stage
IIIA NSCLC [26].
Current restaging algorithms used at the Antwerp Univer-
sity Hospital are depicted in Fig. 2.
3. Surgery for non-small cell lung cancer
(NSCLC)
3.1. Complete R0 resection
The final aim of surgical treatment for non-small-cell lung
cancer (NSCLC) is complete (R0) resection. In this respect,
specific criteria have been established by a working group
of the International Association for the Study of Lung Can-
cer (IASLC) [28]. Complete resection is defined as complete
removal of the primary tumour with no residual macro-
scopic or microscopic tumour left behind; moreover, a sys-
tematic or lobe-specific nodal dissection must have been
performed, and the highest mediastinal lymph node must
be negative.(%) Mortality (%) Sensitivity (%) Negative
predictive
value (%)
Accuracy (%)
0 50 71 78
0 74 86 93
0 71 75 84
0 29 52 60
1 70 73 84
0 61 85 88
1 74 79 87
erapy; CT–RT, chemoradiotherapy.
Table 4 – Types of operative procedures
Standard:
Fig. 2 – Flow chart for mediastinal restaging of non-small-cell lung cancer (NSCLC) in the Antwerp University Hospital
depending on whether a minimally invasive procedure or mediastinoscopy was initially performed. ES, endosonographic
technique (endobronchial or endoscopic ultrasound); MS, mediastinoscopy; PET–CT, integrated positron emission
tomography and computed tomography; RT, radiotherapy; ReMS, repeat mediastinoscopy
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pare surgery versus radiotherapy in the treatment of early-
stage NSCLC, surgical resection has traditionally been consid-
ered the treatment of choice. Markedly improved survival
rates are reported in surgical series in comparison to patients
who did not undergo surgical resection for a variety of rea-
sons [29]. Early-stage disease and T3N1 NSCLC are considered
definite indications for surgery.
Resectability and operability of a primary NSCLC depend
not only on the clinical and intraoperative staging of the tu-
mour, but also on the functional capacity of the patient. So,
detailed cardiopulmonary evaluation to determine the func-
tional status is equally important as this might impact on
the extent of resection [30]. After definitive pathological
examination, a distinction can be made between R0 resec-
tions when there is no residual tumour, R1 with micro-
scopic residual tumour and R2 with macroscopic residual
tumour.Lobectomy
Bilobectomy
Pneumonectomy
Lung-parenchyma-sparing operations:
Proximal Bronchotomy
Rotating bronchoplasty
Bronchial or tracheal wedge excision
Bronchial or tracheal sleeve resection
Distal Anatomical segmentectomy
(wide) Wedge excision
Extended procedures (lung + other structure):
Pericardium (intrapericardial pneumonectomy)
Diaphragm
Chest wall (ribs, vertebrae)
Superior sulcus (Pancoast tumour)3.2. Types of lung cancer resection
Lung cancer resections can be divided into three major groups
(Table 4).
Group 1 – standard resections: standard resections include
lobectomy (removal of a lobe), bilobectomy (removal of two
lobes on the right side) and pneumonectomy (removal of an
entire lung). Pneumonectomy was initially considered as the
treatment of choice in the years 1940–1950, whilst lobectomy
was reserved for patients with diminished pulmonary or car-
diac reserve. In later years, lobectomy was found to provide a
similar survival rate as pneumonectomy if the lesion could be
totally resected by lobectomy.Group 2 – lung parenchyma saving operations: these opera-
tions can be divided into proximal and distal procedures.
The proximal interventions comprise all bronchoplastic and
tracheoplastic operations. The most frequently performed
bronchoplastic procedure is a sleeve resection of the right
upper lobe for a lung cancer invading the upper lobe orifice.
The very first sleeve resection was performed in 1947 for a
carcinoid tumour in the right upper-lobe orifice in an Air
Force cadet to avoid a pneumonectomy which would have
precluded his career as a pilot [31]. Distal procedures include
segmentectomies and wedge resections.
Regarding the extent of resection, lobectomy is generally
considered the procedure of choice in cancers confined to a
Table 5 – Regional lymph-node mapping into zones and
stations according to the 7th tumour-node-metastasis
(TNM) edition [41].
Supraclavicular zone:
1. Low cervical, supraclavicular and sternal notch
Upper zone:
2. Upper paratracheal
3. a. Prevascular
b. Retrotracheal
4. Lower paratracheal
Aortopulmonary (AP) zone:
5. Subaortic or Botallo’s
6. Para-aortic (ascending aorta or phrenic)
Subcarinal zone:
7. Subcarinal
Lower zone:
8. Para-oesophageal (below carina)
9. Pulmonary ligament
Hilar/interlobar zone:
10. Hilar
11. Interlobar
Peripheral zone:
12. Lobar: upper, middle and lower lobe
13. Segmental
14. Subsegmental
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 1 0 –1 2 2 115single lobe. This attitude resulted from a prospective random-
ised trial from the Lung Cancer Study Group comparing lobec-
tomy to lesser resections for peripheral clinical T1N0 lesions
[32]. Patients were randomised to standard lobectomy or les-
ser resection during thoracotomy. Noteworthy in this study
was that nearly half of the patients had a contraindication
to randomisation, mostly because of location of the tumour
or unexpected N1 or N2 disease. Patients who underwent a
limited resection were found to have a tripling of local recur-
rence rate, a 30% increase in overall death rate and a 50% in-
crease in cancer-related death rate in comparison to
lobectomy patients. However, these results were only signifi-
cant at a P-value level of 0.10.
The role of sublobar resection, anatomical segmentectomy
or wide-wedge resection is being reconsidered for very early
lung cancer following large screening programmes for lung
cancer. This is due to the findings of non-solid or part-solid
ground glass opacities, so-called GGOs [33]. This will be fur-
ther discussed with the newly introduced adenocarcinoma
classification.
Group 3 – extended operations: extended operations involve
resection of lung parenchyma with an adjacent organ or
structure invaded by the tumour. Examples include resection
of the chest wall, diaphragm, pericardium, left atrium, supe-
rior vena cava and apex of the chest in superior sulcus tu-
mours. En bloc resection of the locally involved
extrapulmonary structure is advised to avoid tumour spillage
and to ensure a complete R0 resection with negative
margins.
3.3. Different thoracic approaches
A posterolateral thoracotomy incision is the classical inci-
sion performed for lung cancer resection. If feasible, a mus-
cle-sparing thoracotomy is preferred to preserve the
latissimus dorsi muscle. Sternotomy may be used in patients
requiring bilateral procedures, especially bilateral upper-lobe
lung cancers. An extended incision such as a hemi-clam-
shell incision is utilised in selected patients requiring an ex-
tended resection. At the present time, VATS is increasingly
being used as specific access to the thoracic cavity. In a ser-
ies of 1100 VATS lobectomies, excellent results were re-
ported, with an operative mortality of 0.8% [34]. Morbidity
generally appears to be lower with the VATS approach,
although in a nationwide database of 13,619 patients who
underwent lobectomy by thoracotomy or VATS, patients
who underwent VATS lobectomy were 1.6 times more likely
to have intraoperative complications [35]. A recent system-
atic review and meta-analysis of randomised and non-ran-
domised trials concluded that VATS lobectomy is an
appropriate procedure for selected patients with early-stage
NSCLC [36]. Currently, VATS has become a standard ap-
proach for peripheral wedge resections and lobectomy for
stage I tumours. VATS segmentectomy is much less widely
performed and its potential benefits and limitations still re-
quire further evaluation [37,38].
Although VATS seems to be equal or even beneficial in
terms of morbidity, length of stay and survival in comparison
to an open approach, further evaluation in large, prospective
randomised trials is necessary [39].3.4. Intraoperative staging – systematic nodal dissection
Detailed intraoperative systematic lymph node dissection is
important to provide an accurate pathological TNM staging.
The different intrathoracic lymph-node stations were origi-
nally described by Naruke et al. in 1978 [40] and were recently
updated in the 7th TNM classification where the concept of
nodal zones was introduced [41]. The nodal zones and sta-
tions are listed in Table 5 [41,42].
Thoracotomy provides the final investigation and determi-
nation of resectability.
Non-resectable tumours include T4 tumours with invasion
into important adjacent structures or tumours with extensive
mediastinal metastases. These include involvement of vital
mediastinal structures or extracapsular N2 and N3 diseases.
For resected N2 disease, invasion of the highest mediastinal
lymph node heralds a poor prognosis. Massive involvement
of hilar structures is generally a contraindication unless an
intrapericardial pneumonectomy can be performed. Pleural
metastases are also a contraindication to resection due to a
poor long-term survival.
When deciding on the type of operation to be performed,
the surgeon should first perform a careful intraoperative
exploration, taking into account several strategic points. He/
she should determine whether the tumour is peripheral or
central, which lymph nodes are involved, and whether or
not there is transgression of the fissure. Frozen-section anal-
ysis of suspicious lymph nodes or margins can be helpful in
determining the extent of resection. Whenever possible,
lobectomy remains the procedure of choice. Pneumonectomy
is considered ‘a disease in itself’ due to its profound respira-
tory and haemodynamic implications and associated higher
Table 6 – IASLC/ATS/ERS classification of lung adenocarci-
noma in resection specimens [51–53]. Table reproduced with
permission from Wolters Kluwer Health.
Preinvasive lesions:
Atypical adenomatous hyperplasia
Adenocarcinoma in situ (63 cm, formerly BAC)
- non-mucinous
- mucinous
- mixed mucinous/non-mucinous
Minimally invasive adenocarcinoma (63 cm lepidic
predominant tumour with 65 mm invasion):
- non-mucinous
- mucinous
- mixed mucinous/non-mucinous
Invasive adenocarcinoma:
Lepidic predominant (formerly non-mucinous
BAC pattern, with >5 mm invasion)
Acinar predominant
Papillary predominant
Micropapillary predominant
Solid predominant with mucin production
Variants of invasive adenocarcinoma
Invasive mucinous adenocarcinoma (formerly mucinous
BAC)
Colloid
Foetal (low and high grade)
Enteric
BAC, bronchioloalveolar carcinoma.
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tients, however, have adapted to living with just one lung
[43]. A sleeve lobectomy should be considered as an alterna-
tive whenever technically feasible, providing that a complete
resection can be obtained [44].
In a large series of 334 patients operated for lung cancer
invading the chest wall, 5-year survival rate was 32% in pa-
tients who underwent a complete resection, in contrast to
only 4% for incomplete resections, and 0% for exploration
only [45]. Long-term survival was mainly dependent on nodal
involvement and complete resection, and less dependent on
the depth of chest wall invasion.
For precise N staging during thoracotomy, a systematic no-
dal dissection is performed as advocated by Graham et al.
[46]. In this technique, dissection of the mediastinal, hilar
and lobar lymph nodes proceeds in a systematic fashion. In
their classical paper Graham et al. reviewed 240 patients with
clinical T1–3 N0–1 NSCLC [46]. Preoperative mediastinoscopy
was performed when lymph nodes larger than 1.5 cm were
present on chest CT. The rate of exploratory thoracotomy
without further resection was only 3%. Following surgical
resection pathological N2 disease was found in 20% of pa-
tients. There was no subgroup with 0% incidence of N2
involvement and skip metastases were found in 34% of pa-
tients with N2 disease. Peripheral tumours less than 2 cm
had a 24% incidence of lymph-node metastases. Systematic
lymph-node dissection is currently considered the gold stan-
dard for the accurate staging of nodal (N) disease and should
be routinely performed, also when a minimally invasive ap-
proach is chosen.
In a non-randomised study of 373 patients, complete
mediastinal lymph-node dissection identified more levels
of N2 disease in patients with stages II and IIIA NSCLC,
and was associated with improved survival in comparison
to systematic nodal sampling but only for right-sided lesions
[47]. A survival advantage of complete mediastinal lymph-
node dissection has only been demonstrated in one prospec-
tive randomised trial [48]. In a recently published multicen-
tre prospective clinical trial, patients with intraoperatively
staged T1-2N0-non-hilar N1 NSCLC were randomised to
lymph-node sampling versus systematic nodal dissection.
The latter identified occult disease in 3.8% of patients but
was not associated with a benefit in overall survival [49].
However, all patients in this trial were carefully staged with
invasive, pathological analysis of four lymph-node stations.
These results should not be generalised to higher-stage
tumours.
The technique of systematic lymph-node dissection on the
right side includes the dissection of the upper (level 2R) and
lower (level 4R) paratracheal nodes, subcarinal (level 7),
para-oesophageal (level 8R) and inferior pulmonary ligament
(level 9R) lymph-node stations. On the left side, the aortopul-
monary, para-aortic and lower paratracheal nodes (levels 5, 6,
4L), and levels 7, 8L and 9L should be resected.
N1 disease also represents a heterogeneous group of dis-
eases. This was demonstrated by Riquet et al., who reported
a series of 1174 patients with NSCLC; 22% of the patients
had N1 disease, with a 5-year survival of 47.5% [50]. A dis-
tinction was made between intralobar N1 (levels 12 and
13) and extralobar hilar N1 (levels 10 and 11) diseases.Five-year survival rate for intralobar N1 was 54% and for hi-
lar N1 39%. This difference was highly significant. The prog-
nosis of intralobar N1 is similar to N0 disease, and
extralobar N1 is more closely related to N2 with single-sta-
tion involvement.4. Surgical implications of the new
adenocarcinoma classification
4.1. New categories
In early 2011, a new adenocarcinoma classification was pub-
lished by a common working group of the IASLC, the Ameri-
can Thoracic Society (ATS) and the European Respiratory
Society (ERS) [51–53]. This classification is listed in Table 6.
Of special interest to thoracic surgeons are the new cate-
gories adenocarcinoma in situ (AIS) which represents small
(63 cm) solitary adenocarcinomas consisting purely of lepidic
growth without invasion, and minimally invasive adenocarci-
noma (MIA) with 60.5 cm invasion. AIS and MIA were intro-
duced because the 5-year disease-free survival approaches
100% if the tumours are completely resected. The term bron-
chioloalveolar carcinoma (BAC) is no longer utilised as it ap-
plies to five different categories in the new classification,
which gave rise to much confusion [51].
With the advent of helical CT and screening trials in high-
risk populations, there is a renewed interest in small nodules,
especially those with ground-glass opacity (GGO). Recently,
results of the National Lung Screening Trial were published
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were randomised between screening with low-dose CT or
chest radiography. In the CT group, there was a relative reduc-
tion in mortality from lung cancer of 20.0% and a reduction in
death from any cause of 6.7% [54].
Whether some of these lesions can be treated by limited
resection – so-called sublobar resection comprising anatomi-
cal segmentectomy or wedge excision – is currently the sub-
ject of intensive investigation [53]. For a limited resection to
be oncologically valid, a precise pre- and intraoperative diag-
nosis becomes imperative. In terms of preoperative diagnosis,
specific criteria on chest CT as percentage GGO, tumour sha-
dow disappearance rate and histogram analysis have been
shown to have a high predictive value [55]. The role of PET
and integrated PET–CT scanning and specific tumour markers
is currently being evaluated [56].
4.2. Sublobar (limited) resection for lung cancer
The detection rate of smaller lung cancers in recent times is
increasing, and therefore the appropriateness of lobectomy
for stage I lung cancer, especially those tumours 62 cm (clin-
ical T1a disease), is again being questioned [33,57]. Recently,
there have been numerous publications suggesting that sub-
lobar resection for early lung cancers may be an adequate sur-
gical treatment. Many of these studies are retrospective and
not randomised [58–60]. Most reports showed no difference
in survival or in locoregional recurrence between lobectomy
and sublobar resection for tumours 62cm in size. Patients
with GGO tumours on CT have been reported to have a
100% survival at 5 years after resection [61–64]. However, pos-
sible delayed cut-end recurrences have been described after
limited resection of GGO lesions [65].
Two recent reviews and one meta-analysis of sublobar
resection concluded that the well-selected use of sublobar
resection, especially for pure AIS 62 cm, yielded survival
and recurrence rates comparable to those of lobectomy [66–
68]. Thus, sublobar resection is generally considered accept-
able for GGO lesions or adenocarcinomas with minimal inva-
sion. Lobectomy is still considered the standard surgical
treatment for tumours 62 cm in size that have a solid appear-
ance on CT because such tumours are invasive carcinomas.
Definite recommendations can only be made when the re-
sults of large randomised trials such as Japan Clinical Oncol-
ogy Group (JCOG) 0802 in Japan, CALGB 140503 in North
America and European Institute of Oncology (IEO) S638/311
in Italy become available. These trials randomise patients
with tumours 62 cm between lobectomy and sublobar
resection.
Whether a purely anatomical segmentectomy provides a
similar or better result to a wide-wedge resection has not
yet been clearly determined. When correlating CT findings
of GGO with histopathology, many of these lesions corre-
spond to non-invasive forms of neoplastic growth. [61–
64,69,70]. In a recent prospective study from Japan (JCOG
0201), radiological non-invasive peripheral lung adenocarci-
noma was defined as an adenocarcinoma 62.0 cm with
60.25 consolidation [71].
Recent guidelines and a large, randomised screening trial
state that small nodules 610 mm or 6500 mm3 that areclearly 100% pure GGO lesions on chest CT, which are sus-
pected to be AIS or MIA, be considered for close follow-up
rather than immediate surgical resection [72,73]. Specific CT
characteristics to be considered are size, attenuation, shape
and growth rate.
4.3. Systematic lymph-node dissection for early-stage
adenocarcinoma
In some specific subsets of very early-stage adenocarcinoma,
especially pure GGO lesions, systematic lymph-node dissec-
tion may not always be required [74]. Recent analysis of the
Italian COSMOS screening study showed that systematic no-
dal dissection can be avoided in the early stage – clinically
N0 lung cancer when the maximum standardised uptake va-
lue on PET scanning is <2.0 and the pathological nodule size is
610 mm – as the risk of nodal involvement is very low in this
subset of patients [75].
In a Japanese prospective study, a specific treatment algo-
rithm has been proposed [76]. Lesions 610 mm of any type or
pure GGO nodules were initially observed and discussed with
each specific patient. When size or density increased, they
were subsequently resected. GGO lesions 11–15 mm were
treated by segmentectomy and lymph-node sampling. Solid
lesions of 11–15 mm and GGO lesions of 16–20 mm were re-
moved by segmentectomy combined with lymph-node dis-
section. Solid lesions of 16–20 mm were resected by
lobectomy with lymph-node dissection. Applying this algo-
rithm, an excellent 5-year disease-free survival rate of 98%
was observed for limited resection [76].5. Quality of life after lung cancer resection
Although mortality and major morbidity rates offer a patient
valuable information, these data alone are inadequate in
meeting the growing needs for detailed comparison of surgi-
cal approaches and rising expectations of patients. Patients
may regard immediate postoperative complications as an
acceptable risk, but are not prepared to accept significant
postoperative quality of life (QoL) impairments [77]. Several
publications focus on predictors of QoL after early-stage lung
cancer resection. Extent of resection [78–80], surgical ap-
proach [81,82], age [83–85] and smoking status [86–88] are con-
sidered to be significant.
The extent of resection has a significant influence on the
QoL evolution. Several publications evaluated QoL after lobec-
tomy and pneumonectomy [78–80]. Literature data agree that
the initial limitations in the physical QoL component ob-
served after both resections are more pronounced after pneu-
monectomy. Depending on the specific publication, both
resections yielded comparable results after 3–6 months. Sub-
lobar resections, indicated in stage IA patients with a tumour
located in the periphery of the lung and <2 cm in diameter,
are currently often performed. Although these procedures im-
ply a parenchyma-sparing intent, QoL has rarely been re-
ported after sublobar resections. Pompeo et al. evaluated
patients with severe emphysema undergoing a sublobar
resection for stage I lung cancer [89]. Significant improve-
ments were reported in the domains of the physical QoL com-
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fect. Saad prospectively described the evolution in QoL after
different lung resections [90]. A comparable improvement in
the physical QoL was seen after lobectomy as well as after
sublobar resection.
The effect on QoL not only of the muscle-sparing versus
the non-muscle-sparing thoracotomy, but also of minimally
invasive thoracic surgery was recently evaluated. The effect
of the muscle-sparing thoracotomy is mostly seen on the
physical QoL component, with improved shoulder function
and less thoracic pain compared to the non-muscle sparing
thoracotomy [91]. The advantages of VATS over thoracotomy
in terms of QoL are found in the immediate postoperative per-
iod. After postoperative day 4, no significant differences in
QoL are seen [92]. After a VATS procedure Landreneau et al.
found that patients experienced significantly less pain only
on the first 2 days in comparison to a muscle-sparing thora-
cotomy [93].
Conclusions of QoL research in younger patients cannot be
transferred blindly to septuagenarians. Several authors pro-
spectively evaluated QoL after lung-cancer surgery in an el-
derly patient population. In general, age >70 years is an
important risk factor for impairment of the physical QoL com-
ponent, and recovery is not guaranteed until P24 postopera-
tive months [78]. After lobectomy as well as pneumonectomy,
the emotional component returns to baseline the first
3 months after surgery in elderly patients and may reflect a
so-called response shift whereby patients adapt their stan-
dards and perceptions to their expectations and rate their
personal situations better than would otherwise be expected
[94].
Several authors compared QoL between patients aged less
versus more than 70 years. Salati et al. compared QoL after
lobectomy [83]. Preoperatively, elderly patients scored worse
on the physical component of QoL, but scored higher values
on the emotional component. At 3 months after surgery, no
significant differences were seen between the two patient
groups. Burfeind et al. evaluated the effect of lobectomy on
patients who were younger versus older than 70 years [84].
Both groups demonstrated a similar decrement in QoL with
a parallel return to baseline. The one notable exception was
in the physical QoL component, which had returned to base-
line by 6 months in young patients and stayed impaired in pa-
tients P70 years at 6 and 12 months postoperatively.
The effect of smoking habits on postoperative QoL at
6 months was evaluated by Myrdal et al. [87]. Patients who
continued smoking after lung-cancer surgery had signifi-
cantly lower scores for the emotional QoL component than
former smokers and those who had never smoked. In con-
trast, Sarna et al. could not withhold the smoking status
as predictive for postoperative QoL [88]. In a recent study,
we concluded that smoking cessation is beneficial at any
time point prior to lung-cancer resection [86]. Current smok-
ing at the time of surgery is associated with a longer impair-
ment of QoL functioning as well as symptom scores. Since
smoking status is one of the few prognostic factors in the di-
rect control of the patient, this study offers valuable infor-
mation to promote smoking cessation before lung-cancer
surgery.There is an ongoing debate on the effect of induction and
adjuvant chemotherapy or radiotherapy on QoL after lung-
cancer surgery [95–97]. Several authors evaluated the effect
of chemotherapy on the QoL of lung-cancer patients, in both
non-surgical and surgical patients. In non-surgical patients,
chemotherapy was associated with worse QoL, unless the pa-
tient responded to treatment [98]. Paull et al. reported that
exposure to postoperative chemotherapy was a risk factor
for poor QoL after surgery for early-stage lung cancer [97].
These results are not consistent with the study of Fiedler
et al. who evaluated QoL after pneumonectomy comprising
early- as well as advanced-stage lung cancer [96]. Adjuvant
chemotherapy had no significant influence on QoL at
6 months.
Although many questions remain concerning QoL evolu-
tion after lung-cancer surgery, QoL data are essential in prop-
er patient counselling and may create realistic postoperative
objectives for patients. The real challenge in the management
of lung-cancer patients consists not only in improving prog-
nosis but also in maintaining or increasing QoL.6. Surgical quality control
Thoracic surgery comprises a large variety of different proce-
dures which may prove to be technically challenging, such as
extended resections of the superior sulcus, sleeve resections,
intrapericardial procedures and extensive operations after
induction therapy. For this reason uniform judgment of surgi-
cal quality is difficult to perform. Overall mortality is only a
crude parameter and risk stratification is necessary. More-
over, dedicated anaesthesiological, intensive-care and nurs-
ing management is required to obtain the best
postoperative results; thus team management will not only
determine the short-term results but also long-term outcome.
This also implies that hospital volume may be a critical
determinant.
Is there a clear relationship between surgeon or hospital
volume and final outcome? In a seminal paper Luft et al. dem-
onstrated that mortality after open-heart surgery, vascular
surgery and prostatectomy decreases with increasing number
of procedures performed [99]. When analysing data from uni-
versity reports, Hillner et al. showed a relationship between
volume and outcome for complex intra-abdominal and
lung-cancer interventions [100]. When looking at the specific
number of pulmonary resections, mortality was lower in
those centres performing more than 24 interventions on a
yearly basis. Mortality of lobectomy was significantly lower
when performed by a thoracic surgeon compared to a general
surgeon. The latter finding was confirmed in a more recent
study [101]. In another analysis of more than 2000 pulmonary
resections, low-volume centres were compared to high-vol-
ume institutions. Morbidity was lowest and survival highest
in those centres performing more than 67 resections per year
[102]. Also in a Flemish, multicentre, hospital-based lung-can-
cer registry, mortality decreased when hospital volume in-
creased [103]. The same holds true for oesophagectomy
[104]. In the latter paper, mortality after lung resection was
not related to technical factors but mainly to severe postoper-
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cated multidisciplinary team in taking care of this patient
population.
Are results different in teaching hospitals with specific
thoracic surgical residents? In a recent analysis of 498,099
lung resections a superior outcome was found in hospitals
with a thoracic surgery residency programme [105]. The odds
ratio of death in patients undergoing pneumonectomy was
reduced by more than 30% compared with hospitals providing
training in general surgery.
Although evidence-based minimal volume standards are
currently lacking, a recent systematic review and meta-anal-
ysis concluded that hospital volume and surgeon specialty
are important determinants of outcome in lung-cancer resec-
tions [106].
So, centralisation of care seems to be the logical conse-
quence in improving short-term and long-term results. How-
ever, most of the presented data come from North America
with established training programmes in thoracic and cardio-
thoracic surgery. What is the current situation in Europe?
In many European countries, general thoracic surgery cur-
rently exists as a separate specialty. However, the precise
number of centres performing thoracic surgical procedures
is unknown and accurate figures on the total number of inter-
ventions are not currently available. Certification in thoracic
surgery is not uniform throughout Europe. As an example,
thoracic surgery is not a specifically defined entity in Belgium,
where it falls within the discipline of general surgery together
with abdominal, cardiac, vascular, paediatric and trauma
surgery.
There is also no uniform European training programme in
thoracic or cardiothoracic surgery. To establish a more precise
structure of general thoracic surgery a working group has
been established by the European Association for Cardio-tho-
racic Surgery (EACTS) and the ESTS. Recently, the Union
Europe´enne des Me´decins Spe´cialistes (UEMS) has created a
specific thoracic surgical division related to the general and
cardiothoracic surgical sections. Specific criteria for training
and accreditation in thoracic surgery are currently being
developed.
To obtain more precise data on the number of general tho-
racic surgical procedures in Europe, several large databases
have been created. The ESTS created a voluntary database
for general thoracic surgery. In 2011 a total of 24,574 lung
resections were reported, including all diagnoses. Lobectomy
represented 57.5% of cases, and pneumonectomy 9.5%. A to-
tal of 16,710 cases of primary lung cancer were reported,
lobectomy and bilobectomy being performed in 76% of cases.
In this database mortality and morbidity are calculated
according to specific risk scores, allowing benchmarking be-
tween different units and countries.
To ensure high-quality patient care in thoracic surgery, the
EACTS/ESTS working group felt that it should be performed
within the logistical and economical framework of specialised
units. These units should be designed to allow patient care
and treatment according to recommended standards, as well
as education of surgical trainees, continuous development
and research in thoracic surgery. The working group proposed
two types of thoracic surgical centres: highly specialised cen-
tres within or associatedwith a university, performing at least250 major thoracic procedures per year, and standard units
which are free-standing or combined with cardiac, vascular
or general surgery. In a standard unit at least 100 major inter-
ventions should be performed annually. Lung transplantation
and its alternative procedures should be performed only in
centres with special interest and with cardiac surgical facili-
ties. According to well-defined criteria in combination with
an on-site visit, dedicated thoracic units can obtain an insti-
tutional quality certification in general thoracic surgery.
In order to raise the profile of thoracic surgery in Europe,
further harmonisation is necessary. Unified databases should
become available, detailing not only mortality but also spe-
cific outcome measures related to morbidity, survival and
quality of life. Postgraduate education remains necessary to
ensure a high quality of thoracic surgical interventions as
has recently been demonstrated by a study from the Nether-
lands evaluating completeness of lymph-node dissection in
dedicated thoracic surgical centres [107,108].
Thoracic surgeons should be further involved in random-
ised clinical trials comparing newly introduced treatment
modalities – such as stereotactic radiotherapy or radiofre-
quency ablation – to classical surgical procedures. They
should also be prepared to adapt to a new, constantly chang-
ing environment. Multidisciplinary collaboration and large-
scale prospective studies are necessary to update current
diagnostic and therapeutic algorithms ensuring optimal pa-
tient care in thoracic surgery [109].Conflict of interest statement
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